Summit Tx Capital, L.P. Akero Therapeutics, Inc. Put Options Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
270Shares Held
85.9MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$292 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$278 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$233 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$220 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$206 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.83B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...